Ligand Pharmaceuticals Incorporated has reported robust financial results for the third quarter of 2026, showcasing a significant increase in royalty revenue. The company announced a 51% year-over-year growth in royalty revenue, reaching $70.3 million. This strong performance has led Ligand to raise its full-year adjusted diluted earnings per share (EPS) guidance to between $9.50 and $9.75.

The announcement, made on October 29, 2026, is crucial for Ligand as it reflects the company's successful execution of its royalty aggregation strategy. The increase in revenue is attributed to contributions from the XOMA portfolio and continued commercial momentum across key assets, including Filspari, a product from Travere Therapeutics.

Background

Ligand Pharmaceuticals Inc, incorporated in Delaware, operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol LGND and has a range of other tickers for different classes of stock. Ligand is categorized as a large accelerated filer and has a fiscal year ending on December 31.

What the Filing Says

The filing indicates that Ligand's third-quarter results reflect ongoing strength in its royalty business. According to the press release included in the filing, "Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari." Additionally, the company reported total revenues and income of $78.7 million for the quarter, although this figure reflects a decrease compared to the previous year due to prior-year divestiture-related income.

Impact

This financial update is significant not only for Ligand but also for its competitors in the pharmaceutical preparations industry. Companies that rely on similar royalty-based revenue models may need to reassess their strategies in light of Ligand's success. The strong financial performance could influence investor perceptions and market dynamics within the sector.

What's Next

Looking ahead, Ligand Pharmaceuticals is expected to provide an updated five-year outlook during its investor day scheduled for December 8. The filing does not specify any immediate actions required from shareholders or additional filings expected in the near term.